Home » Newsletters » BioWorld Science

BioWorld Science

March 31, 2005

View Archived Issues

XenoPort advances XP-19986 into phase I trials

Xcyte Therapies refocuses resources and activities

Arius' ARH-460-16-2 antibody to be studied for IBD

Keryx finalizes SPA agreement for KRX-101

PhG-alpha1 shows effectiveness on NSCLC cells in lab test

NIAID opens phase I study of experimental avian flu vaccine

Tanox to acquire Sunol's tissue factor antagonist program

Dyax updates DX-88 progress for HAE

Praecis in discussions regarding German Plenaxis submission

Enrollment completed in phase I/II CLL study of HuMax-CD20

NS-2359 advanced into phase II

IND accepted for MORAb-003

J&J and Guidant merger registration declared effective

CG-53135-05 shows no immunogenicity in patients with chemotherapy-induced mucositis

New evidence confirms the benefits of finasteride in the prevention of prostate cancer

Gene therapy claimed for the treatment of pain

A method for predicting colorectal cancer reported by Chiron

New treatments for cancer disclosed by Roche

New patents cover treatments for Alzheimer's disease

AZD-0865 effectively blocks acid output in preclinical tests

PHA-533533 displays a desirable anticancer preclinical profile

KMI-429 reduces beta-amyloid production in mice

VDM-11 produces antitussive effect in mice

12,14-Di-Cl-DHAA improves survival of postischemic myocytes

Approvable letter for Combidex

Takeda discontinues antidiabetic agent TAK-559

Enbrel launched in Japan

Eisai seeks European approval of Inovelon for Lennox-Gastaut Syndrome

Baraclude receives FDA approval

Zofran approved for children aged one month and older

Depo-subQ provera 104 approved for management of endometriosis pain

Once-monthly Boniva receives FDA approval

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 30, 2025.
Today's news in brief
Briefs
BioWorld MedTech briefs for Jan. 30, 2026.
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...
5-HT2R allosteric ligands attenuate cocaine use and seeking behavior
BioWorld Science
Serotonergic G-protein-coupled receptors (GPCRs), including the 5-HT2A receptor (5-HT2AR) and 5-HT2CR, are key regulators of cortical signaling pathways and...